JPMorgan Chase & Co. Purchases 57,174 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

JPMorgan Chase & Co. raised its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 42.3% during the third quarter, HoldingsChannel.com reports. The firm owned 192,456 shares of the company’s stock after acquiring an additional 57,174 shares during the quarter. JPMorgan Chase & Co.’s holdings in Kiniksa Pharmaceuticals International were worth $7,473,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of KNSA. USA Financial Formulas bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $32,000. EverSource Wealth Advisors LLC lifted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. Quarry LP bought a new position in Kiniksa Pharmaceuticals International in the third quarter valued at approximately $44,000. Osaic Holdings Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. Finally, Farther Finance Advisors LLC grew its holdings in Kiniksa Pharmaceuticals International by 582.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after acquiring an additional 1,159 shares during the period. Institutional investors own 53.95% of the company’s stock.

Insider Activity

In other news, CFO Mark Ragosa sold 17,845 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the sale, the chief financial officer owned 12,086 shares of the company’s stock, valued at $523,082.08. This trade represents a 59.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Barry D. Quart sold 12,528 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $45.27, for a total value of $567,142.56. Following the transaction, the director owned 12,546 shares in the company, valued at $567,957.42. This trade represents a 49.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 48,605 shares of company stock worth $2,122,646. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $45.70 on Tuesday. The firm’s fifty day moving average is $45.01 and its two-hundred day moving average is $41.59. The firm has a market cap of $3.50 billion, a PE ratio of 61.76 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.25 and a twelve month high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. During the same period last year, the firm earned ($0.12) EPS. Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% on a year-over-year basis. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective for the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.